UPPER GASTROINTESTINAL EVENT REDUCTION AND CARDIOVASCULAR SAFETY OF ANTIPLATELET THERAPY WITH PA32540, A TABLET WITH ENTERIC-COATED ASPIRIN AND IMMEDIATE-RELEASE OMEPRAZOLE: RESULTS OF TWO 6-MONTH, PHASE 3 STUDIES

(1) University of Zaragoza

(2) NorthShore University Health System

(3) University of Michigan Medical Center

(4) POZEN Inc.



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS I session at UEG Week 2013

This item can be cited as: United European Gastroenterology Journal; 2013: 1 (Supplement 1) A252

Categorisation:

  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2013